2018
DOI: 10.4103/ijh.ijh_39_17
|View full text |Cite
|
Sign up to set email alerts
|

Thyroid dysfunction in chronic myeloid leukemia patients on nilotinib

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 2 publications
0
2
0
Order By: Relevance
“…The International Randomized Study of Interferon and STI571 (IRIS) is considered a landmark clinical trial for CML treatment with TKIs. Imatinib selectively inhibits BCR-ABL competitively, as well as several other kinases, including stem cell factor receptor (KIT), platelet-derived growth factor receptor (PDGFR), and colony-stimulating factor receptor-1 (CSF-1R) [ 8 ]. Other TKIs, such as dasatinib, nilotinib, bosutinib have also been used in CML patients.…”
Section: Introductionmentioning
confidence: 99%
“…The International Randomized Study of Interferon and STI571 (IRIS) is considered a landmark clinical trial for CML treatment with TKIs. Imatinib selectively inhibits BCR-ABL competitively, as well as several other kinases, including stem cell factor receptor (KIT), platelet-derived growth factor receptor (PDGFR), and colony-stimulating factor receptor-1 (CSF-1R) [ 8 ]. Other TKIs, such as dasatinib, nilotinib, bosutinib have also been used in CML patients.…”
Section: Introductionmentioning
confidence: 99%
“…The impact of bacteria IAA‐producer on plants appeared varied from pathogenesis to phyto‐stimulation [3] . The coordination feature of HIAA hormone led to its use for preparing Co(II), Ni(II), Cu(II) and Pt(IV) complexes [4] . Such complexes were characterized and elucidated by analytical and spectral aspects.…”
Section: Introductionmentioning
confidence: 99%